Contact
searchSearch
HMP Global

Advertisement

Advertisement

ADVERTISEMENT

Multimedia

Joseph Mikhael, MD, City of Hope Cancer Center
Conference Coverage
Strategies for Treating Patients With Multiply Relapsed Multiple Myeloma
01/19/2024

Featuring Joseph Mikhael, MD

Featuring Joseph Mikhael, MD
At the 2023 Lymphoma, Leukemia & Myeloma Congress, Joseph Mikhael, MD, discusses treatment regimens like CELMoDs and XP01 inhibitors for patients with multiply relapsed multiple myeloma.
At the 2023 Lymphoma, Leukemia & Myeloma Congress, Joseph Mikhael, MD, discusses treatment regimens like CELMoDs and XP01 inhibitors for patients with multiply relapsed multiple myeloma.
At the 2023 Lymphoma, Leukemia &...
01/19/2024
Lymphoma, Leukemia & Myeloma Network
Joseph Mikhael, MD, City of Hope Cancer Center
Conference Coverage
Benefits of MRD Testing for the Treatment of Patients With Multiple Myeloma
01/19/2024

Featuring Joseph Mikhael, MD 

Featuring Joseph Mikhael, MD 
At the 2023 Lymphoma, Leukemia & Myeloma Congress, Joseph Mikhael, MD, participated in a debate on the benefits of minimal residual disease testing in multiple myeloma treatment.
At the 2023 Lymphoma, Leukemia & Myeloma Congress, Joseph Mikhael, MD, participated in a debate on the benefits of minimal residual disease testing in multiple myeloma treatment.
At the 2023 Lymphoma, Leukemia &...
01/19/2024
Lymphoma, Leukemia & Myeloma Network
Elias Jabbour, MD, MD Anderson Cancer Center
Videos
Exploring Chemotherapy-Free Treatment for Patients With Philadelphia-Positive ALL
11/07/2023

Featuring Elias Jabbour, MD

Featuring Elias Jabbour, MD
At the 2023 Lymphoma, Leukemia & Myeloma Congress, Elias Jabbour, MD, discusses if chemotherapy can be eliminated from the treatment of Philadelphia-positive acute lymphoblastic leukemia.
At the 2023 Lymphoma, Leukemia & Myeloma Congress, Elias Jabbour, MD, discusses if chemotherapy can be eliminated from the treatment of Philadelphia-positive acute lymphoblastic leukemia.
At the 2023 Lymphoma, Leukemia &...
11/07/2023
Lymphoma, Leukemia & Myeloma Network
Ruben A. Mesa, MD, FACP, Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Videos
Novel Advances in the Treatment of Patients With Myelofibrosis
11/07/2023

Featuring Ruben A. Mesa, MD, FACP

Featuring Ruben A. Mesa, MD, FACP ...
At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Ruben A. Mesa, MD, FACP, discusses the latest updates in myelofibrosis treatment.
At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Ruben A. Mesa, MD, FACP, discusses the latest updates in myelofibrosis treatment.
At the 2023 Lymphoma, Leukemia &...
11/07/2023
Lymphoma, Leukemia & Myeloma Network
Jason Westin, MD
Videos
Selecting CAR T-Cell Therapy for Older Patients With Diffuse Large B-Cell Lymphoma
11/07/2023

Featuring Jason Westin, MD

Featuring Jason Westin, MD
At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, New York, Jason Westin, MD, participated in a debate regarding choice of CAR T-cell therapy versus novel therapy for older adults with diffuse large B-cell lymphoma.
At the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, New York, Jason Westin, MD, participated in a debate regarding choice of CAR T-cell therapy versus novel therapy for older adults with diffuse large B-cell lymphoma.
At the 2023 Lymphoma, Leukemia &...
11/07/2023
Lymphoma, Leukemia & Myeloma Network
Gareth Morgan, MD, NYU Langone Medical Center
Videos
Role of Tumor Complexity and Microenvironment in the Development of Multiple Myeloma
11/02/2023

Featuring Gareth Morgan, MD

Featuring Gareth Morgan, MD
During the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Gareth Morgan, MD, examines the role of tumor complexity and microenvironment in the development of multiple myeloma.
During the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Gareth Morgan, MD, examines the role of tumor complexity and microenvironment in the development of multiple myeloma.
During the 2023 Lymphoma,...
11/02/2023
Lymphoma, Leukemia & Myeloma Network
Kenneth Anderson, MD, Dana-Farber Cancer Institute
Videos
New Targets on the Horizon for Multiple Myeloma Treatment
11/01/2023

Featuring Kenneth C. Anderson, MD

Featuring Kenneth C. Anderson, MD ...
At the 2023 Lymphoma, Leukemia & Myeloma Congress, Kenneth C. Anderson, MD, discussed existing and promising novel therapies for patients with multiple myeloma.
At the 2023 Lymphoma, Leukemia & Myeloma Congress, Kenneth C. Anderson, MD, discussed existing and promising novel therapies for patients with multiple myeloma.
At the 2023 Lymphoma, Leukemia &...
11/01/2023
Lymphoma, Leukemia & Myeloma Network
Eric Padron, MD, Moffitt Cancer Center
Videos
Updates on the Treatment of Patients With Chronic Myelomonocytic Leukemia
10/24/2023

Featuring Eric Padron, MD

Featuring Eric Padron, MD
During the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Eric Padron, MD, discusses updates regarding managing and treating chronic myelomonocytic leukemia.
During the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Eric Padron, MD, discusses updates regarding managing and treating chronic myelomonocytic leukemia.
During the 2023 Lymphoma,...
10/24/2023
Lymphoma, Leukemia & Myeloma Network
Julie Vose, MD
Videos
Advances in Treatment Options for Patients With T-Cell Lymphoma
10/24/2023

Featuring Julie Vose, MD

Featuring Julie Vose, MD
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Julie Vose, MD, discusses advances in improving outcomes for patients with peripheral T-cell lymphoma.
At the Lymphoma, Leukemia & Myeloma Congress in New York, New York, Julie Vose, MD, discusses advances in improving outcomes for patients with peripheral T-cell lymphoma.
At the Lymphoma, Leukemia &...
10/24/2023
Lymphoma, Leukemia & Myeloma Network
Amer M. Zeidan, MBBS, MHS, Yale
Videos
Novel Treatment Options for Patients With Myelodysplastic Syndromes
10/24/2023

Featuring Amer Zeidan, MBBS, MHS 

Featuring Amer Zeidan, MBBS, MHS  ...
During the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Amer Zeidan, MBBS, MHS, provided insights into novel treatment updates for patients with high and low-risk MDS.
During the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Amer Zeidan, MBBS, MHS, provided insights into novel treatment updates for patients with high and low-risk MDS.
During the 2023 Lymphoma,...
10/24/2023
Oncology

Advertisement

In the News

News
Venetoclax Monotherapy Demonstrates Deep, Durable Responses Among Adult Patients With R/R CLL
07/10/2024
According to phase 3b results from the VENICE-1 trial, venetoclax monotherapy demonstrates durable responses in adult patients with relapsed/refractory chronic lymphocytic leukemia, including B-cell receptor-associated kinase inhibitor...
According to phase 3b results from the VENICE-1 trial, venetoclax monotherapy demonstrates durable responses in adult patients with relapsed/refractory chronic lymphocytic leukemia, including B-cell receptor-associated kinase inhibitor...
According to phase 3b results...
07/10/2024
Lymphoma, Leukemia & Myeloma Network
News
FDA Approval of Lisocabtagene Maraleucel for Patients With R/R Mantle Cell Lymphoma
07/09/2024
The U.S. Food and Drug Administration granted approval to lisocabtagene maraleucel for adult patients with relapsed or refractory MCL who have received at least 2 prior lines of systemic therapy including a BTK inhibitor.
The U.S. Food and Drug Administration granted approval to lisocabtagene maraleucel for adult patients with relapsed or refractory MCL who have received at least 2 prior lines of systemic therapy including a BTK inhibitor.
The U.S. Food and Drug...
07/09/2024
Lymphoma, Leukemia & Myeloma Network
News
Circulating Tumor DNA Monitoring for Patients With Follicular Lymphoma Undergoing CAR T-Cell Therapy
06/26/2023

Jordan Kadish 

Jordan Kadish 
Circulating tumor DNA monitoring demonstrated efficacy as a non-invasive method in correlating treatment responses and monitoring disease progression among patients with follicular lymphoma undergoing CAR T-cell therapy.
Circulating tumor DNA monitoring demonstrated efficacy as a non-invasive method in correlating treatment responses and monitoring disease progression among patients with follicular lymphoma undergoing CAR T-cell therapy.
Circulating tumor DNA monitoring...
06/26/2023
Oncology
News
Efficacy and Safety of Rituximab-Bendamustine vs R-CHOP Among Patients With Follicular Lymphoma
06/26/2023

Jordan Kadish

Jordan Kadish
Rituximab-bendamustine and R-CHOP yielded similar efficacy results, but had distinct safety profiles and long-term events among patients with follicular lymphoma.
Rituximab-bendamustine and R-CHOP yielded similar efficacy results, but had distinct safety profiles and long-term events among patients with follicular lymphoma.
Rituximab-bendamustine and...
06/26/2023
Oncology
News
FDA Grants Accelerated Approval to Glofitamab for Patients With R/R Diffuse Large B-Cell Lymphoma
06/23/2023

Jordan Kadish

Jordan Kadish
On June 15, 2023, the FDA granted accelerated approval to glofitamab-gxbm for the treatment of patients with relapsed/refractory DLBCL, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma after ≥ 2 lines of...
On June 15, 2023, the FDA granted accelerated approval to glofitamab-gxbm for the treatment of patients with relapsed/refractory DLBCL, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma after ≥ 2 lines of...
On June 15, 2023, the FDA...
06/23/2023
Oncology
News
Brentuximab Vedotin Plus Doxorubicin and Dacarbazine for Patients With Nonbulky Limited-Stage Classic Hodgkin Lymphoma
06/23/2023

Jordan Kadish

Jordan Kadish
Results from a phase 2 study indicated that brentuximab vedotin plus doxorubicin and dacarbazine combination treatment showed promise as a treatment for patients with limited-stage classical Hodgkin lymphoma.
Results from a phase 2 study indicated that brentuximab vedotin plus doxorubicin and dacarbazine combination treatment showed promise as a treatment for patients with limited-stage classical Hodgkin lymphoma.
Results from a phase 2 study...
06/23/2023
Oncology
News
Clinical Outcomes After BTK Inhibitor and B-Cell Lymphoma 2 Inhibitor Treatment Among Patients With CLL
06/08/2023

Jordan Kadish

Jordan Kadish
The real-world response rates among patients with CLL/SLL after receiving covalent BTK inhibitor and B-cell lymphoma 2 inhibitor treatment demonstrate a need for more effective follow-up therapies, according to a retrospective real-world...
The real-world response rates among patients with CLL/SLL after receiving covalent BTK inhibitor and B-cell lymphoma 2 inhibitor treatment demonstrate a need for more effective follow-up therapies, according to a retrospective real-world...
The real-world response rates...
06/08/2023
Oncology
News
Ki67 Expression Shows Promise as a Predictive Marker for Follicular Lymphoma
06/08/2023

Jordan Kadish

Jordan Kadish
High follicular Ki67 expression was associated with longer progression-free survival among patients with follicular lymphoma who were treated with R-CHOP immunochemotherapy, suggesting its potential as a predictive marker.
High follicular Ki67 expression was associated with longer progression-free survival among patients with follicular lymphoma who were treated with R-CHOP immunochemotherapy, suggesting its potential as a predictive marker.
High follicular Ki67 expression...
06/08/2023
Oncology

Advertisement

Latest Podcasts

Podcasts
Dr Leonard Shares Highlights to Expect at the 2020 Lymphoma, Leukemia & Myeloma Congress
10/19/2020
John Leonard, MD, discusses what to expect at the virtual 2020 Lymphoma, Leukemia & Myeloma Congress taking place October 21-24, 2020.
John Leonard, MD, discusses what to expect at the virtual 2020 Lymphoma, Leukemia & Myeloma Congress taking place October 21-24, 2020.
John Leonard, MD, discusses what...
10/19/2020
Oncology
What to Expect at the Non-Malignant Hematology Workshop at Lymphoma, Leukemia & Myeloma Congress
Podcasts
What to Expect at the Non-Malignant Hematology Workshop at Lymphoma, Leukemia & Myeloma Congress
08/24/2020
James B. Bussel, MD, gives an overview of what to expect at the brand new Non-Malignant Hematology Workshop and how the content is critical for hematology and oncology practice.
James B. Bussel, MD, gives an overview of what to expect at the brand new Non-Malignant Hematology Workshop and how the content is critical for hematology and oncology practice.
James B. Bussel, MD, gives an...
08/24/2020
Oncology
Podcasts
Seattle Children's Hospital Leukemia Program Offers Multidisciplinary Care to Underserved Population
06/19/2018
Todd Cooper, DO, discusses a new program launched at The Seattle Children's Hospital for patients with high-risk leukemia.
Todd Cooper, DO, discusses a new program launched at The Seattle Children's Hospital for patients with high-risk leukemia.
Todd Cooper, DO, discusses a new...
06/19/2018
Oncology

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use